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Wasting is observed in a large percentage of patients 
receiving peritoneal dialysis (PD) and it is associated 
with functional impairment and worse outcome. In this 
article, we review the current state of our knowledge 
regarding the effects of PD on protein metabolism and 
their possible interactions with the uremia-induced and 
comorbidity-induced alterations in protein metabolism. 
Available evidence shows that glucose-based PD 
induces a new state in muscle protein dynamics which 
is characterized by decreased turnover rates and a 
reduced efficiency of protein turnover, a condition 
which may be harmful in stress conditions, when 
nutrient intake is diminished or during superimposed 
catabolic illnesses. The effects of PD on protein 
turnover may overlap with the effects of aging and 
comorbidities to promote net catabolism. There is a 
need to develop more effective treatments to enhance 
the nutritional and functional status of PD patients. 
New approaches include the use of icodextrin to 
maintain extracellular volume, amino acids/keto acids-
containing supplements combined with physical 
exercise, vitamin D, myostatin antagonism, and ghrelin 
agonism for malnourished patients refractory to 
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More than 272,000 patients receive 
peritoneal dialysis worldwide, representing 
approximately 11% of the global dialysis 
population (1). Despite advances in treatment 
technique, mortality is still high in PD patients, as 
well as in those hemodialysis-treated (2). Besides 
age, cardiovascular disease, diabetes and residual 
renal function, markers of nutritional status, 
including serum albumin and subjective global 
assessment (SGA) remain powerful predictors of 
outcome (2-5).  
In general population and in patients with 
chronic diseases loss of muscle mass is associated 
with adverse outcomes such as functional 
impairment, lower quality of life and increased 
mortality (6). In cohort studies, low appendicular 
muscle mass is associated with mortality in PD 
patients (7). Factors such as exogenous 
malnutrition, low vitamin D levels, insulin/IGF1 
resistance and inflammation can influence the 
development of wasting.  
PD patients are also exposed to catabolic 
stressors such as high glucose load, uremia, 
malnutrition and comorbidities which can 
accelerate the wasting process.  
Assessment of muscle functionality may 
provide additional diagnostic and prognostic 
information to muscle-mass evaluation. Both 
reduced muscle mass and strength are prevalent 
conditions in dialysis patients and predict a worse 
outcome. Of note, muscle strength and muscle mass 
are not necessarily congruent; since muscle strength 
can diminish even though muscle mass is 
maintained or increased.  
In a prospective study of 330 incident 
dialysis patients low muscle strength was more 
strongly associated with aging, protein-energy 
wasting, physical inactivity, inflammation, and 
mortality than low muscle mass (8). Muscle atrophy 
has been showed to be more common in female 
dialysis patients and it is associated with 
 
 
inflammation, poor nutritional and anthropometric 
status (9).  
In France, in the French Language 
Peritoneal Dialysis Registry (RDPLF), 1.7% of 
transfers to hemodialysis and 3.2% of deaths have 
been estimated to be due to malnutrition. Although 
a causal link between malnutrition and patient 
outcome is difficult to prove because of the 
presence of confounders (inflammation and 
comorbidity, for example), identification and 
management of malnourished PD patients should be 
a central target. Traditionally, different terms have 
been used to identify an altered state on nutrition in 
patients on PD: “malnutrition”, “wasting”, “muscle 
atrophy” and “cachexia”. Recently, the diagnostic 
criteria for the wasting syndrome in patients with 
chronic kidney disease (CKD) have been revised 
(10). Notably the occurrence of protein-energy 
wasting (PEW) syndrome (as defined by multiple 
markers of nutritional status) has been reported in a 
percentage of 18% to 56% of this population 
depending on the assessment method used (5).  
Superimposed on factors due to uremia, 
nutritional problems caused by PD can play “per 
se” a role in the pathogenesis of wasting. Peritoneal 
dialysis is most commonly based on the exchanges 
between blood and a glucose-containing peritoneal 
solution, thus exploiting the fluid and solute 
transport characteristics of the peritoneum. One of 
the untoward effects of PD is the loss of proteins 
and amino acids into the dialysate effluent. Patients 
undergoing PD lose amino acids (1–3.5 g a day) 
and a substantial amount of proteins (5–10 g per 
day), mainly albumin (6-8 g), but also 
immunoglobulins, complement, transferrin, β2-
microglobulin, and α2-macroglobulin (11-12-13). In 
particular, the type of peritoneal membrane 
transport might influence the amount of protein 
loss; in high transporters protein losses are 
considerably greater than in patients with a low 
solute transport rate (14). Whether rapid transport 
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Furthermore “inherent” fast transport (that is, 
the fast solute transport rate is from the start of 
peritoneal dialysis) and “acquired” fast 
transport (that is, when the transport rate 
increases with time on peritoneal dialysis) have 
different clinical implications; inherent fast 
transport is associated with worse outcomes 
and increased mortality because it is linked 
with greater levels of comorbidity and 
inflammation than acquired fast transport (15). 
Protein losses markedly increase during 
peritonitis. The continuous loss of proteins and 
amino acids through peritoneal clearance 
accounts for almost a third of the reported 
increase in dietary protein requirements (13) 
and can be compensated by adequate dietary 
intake, but a poor appetite or anorexia limit 
intake in many patients. Balafa et al. 
demonstrated that baseline peritoneal albumin 
clearances and dialysate losses were associated 
with some signs of comorbidity, like the 
presence of a fast peritoneal transport status, 
but this did not have a measurable effect on 
patient survival (16).  
Some major metabolic effects of PD 
can be due to the absorption of glucose. On one 
hand the peritoneal glucose uptake (as much as 
400-800 KCal are provided daily by different 
PD regimens) allows for most PD patients to 
meet the energy intake requirements, in fact the 
caloric load from a single glucose-based 
exchange can contribute to >30% of the total 
daily energy intake of a patient on PD (17). 
Even though it is plausible to think that caloric 
absorption could reduce appetite, the glucose 
absorption from PD fluid did not suppress 
calories or protein intake in a large cohort study 
(18).  
On the other hand, ongoing glucose uptake is 
responsible for the development of truncal 
adiposity, sustained hyperinsulinemia and 
increase in triglycerides, as well as for the 
occurrence or aggravation of atherosclerosis 
which are observed after the initiation of 
 
 
treatment (19). Of note, the survival advantage 
associated with obesity observed in 
hemodialysis (HD) patients appears to be less 
likely in PD patients (20).  
The PD procedure may impair 
appetite by causing abdominal discomfort and 
also through the absorption of the osmotic 
agent and other factors. Furthermore, a delayed 
gastric emptying is often seen in patients on PD 
(21). The mechanism of delayed gastric 
emptying is not clear. It has been proposed that 
the cause might be the elevated indwelling PD 
fluid (22). Other factors may contribute to 
delayed gastric emptying time, as diabetes, 
dialysate glucose reabsorption (23) and 
abnormal gastric myoelectric activity (24). 
Actual protein and energy intakes < 1.0 
g/kg/day and 26 kcal/kg are often reported. An 
increased peritoneal solute transport rate has 
been linked to PEW and also to the 
malnutrition, inflammation, and atherosclerosis 
syndrome, which has been associated to poor 
appetite. The use of new PD solutions free of 
glucose degradation products and at neutral-pH 
has been reported to be associated with higher 
plasma levels of acylated ghrelin and 
adiponectin than classic solutions. These 
findings may contribute to explain improved 
appetite scores rates reported with the use of 
so-called biocompatible PD solutions (25). 
 
Alterations in muscle biology induced by 
uremia 
 
Decrease in nutrient intake, metabolic 
acidosis, physical inactivity and co-morbid 
conditions such as diabetes and sepsis can 
promote muscle wasting through an increase in 
protein degradation and/or a decrease in protein 
synthesis (26). However, uremia per se 
promotes net protein catabolism, as suggested 
by studies in animal models. Bailey et al. 
recently identified a series of abnormal post-
receptor signaling changes in the insulin/IGF-1 
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pathway in muscle of rats with CKD (27). These 
included the occurrence of functional abnormalities 
in the IRS/PI3-K cascade that decrease the 
phosphorylation of Akt. The low phosphorylated 
Akt activity can stimulate the expression of specific 
E3 ubiquitin conjugating enzymes, atrogin-
1/MAFbx and MuRF1. Furthermore, a decrease in 
muscle PI3K activity could activate Bax, leading to 
stimulation of caspase-3 activity and could increase 
apoptosis and protein degradation. These defects 
which are specific to uremia can overlap with those 
due to aging, acidosis, diabetes and sepsis.  
Recently, Zhang et al (28) in a rodent model of 
CKD demonstrated that myostatin is upregulated in 
skeletal muscle and that myostatin suppression 
decreases the levels of circulating inflammatory 
cytokines, including TNF-α and IL-6. In exploring 
the influence of myostatin on these cytokines, they 
observed that TNF-α stimulates myostatin 
expression, whereas myostatin stimulates IL-6 
production. Recently, we (29) observed an 
upregulation of myostatin gene expression in 
skeletal muscle of pre-dialysis CKD patients. 
Myostatin was associated with upregulated IL-6 
expression, suggesting that microinflammatory 
changes taking place in muscle cells and myostatin 
are metabolically linked in CKD patients before the 
start of PD. Recently it has been demonstrated that 
the upregulation of myostatin in skeletal muscle in 
CKD follows an IL-6 dependent stimulation of 
Stat3 to increase the expression of 
CCAAT/enhancer-binding protein δ (C/EBPδ). The 
signalling pathway following binding of myostatin 
to its receptor involves activation of Smad2/Smad3 









fibrinogenemia are frequently observed in PD-
treated patients. Serum albuminl is a powerful 
predictor of outcomes in both HD and PD patients 
(31-34). In a study of 130,052 PD patients, those 
with baseline serum albumin level <3.0 g/dL had a 
more than 3-fold higher adjusted risk of all-cause 
and cardiovascular mortality and 3.4-fold higher 
risk of infection-related mortality. A significant 
increase in death risk was evident for PD patients 
with serum albumin <3.8 g/dL. Of note, 
hypoalbuminemia predicts an increased risk of both 
cardiovascular and infection-related mortality in PD 
patients (34).  
Serum albumin levels are the resultant of 
several processes. These include rate of hepatic 
synthesis of albumin and other proteins, dietary 
protein intake, distribution in the intra/extravascular 
compartments, hydration state, protein losses in the 
peritoneal effluent and urinary protein losses in 
patients with residual renal function and 
degradation of albumin. Both albumin and 
fibrinogen are lost in PD fluid.  
In stable PD patients recommendations for 
dietary protein intake are 1.1-1.3 g/kg/daily (35). 
Protein losses into peritoneal effluent are tipically 
5–10 g per day, mainly albumin (6-8  
g) (11-13) and urinary losses are possible in 
patients with residual kidney function. To 
counterbalance these losses hepatic albumin 
synthesis in the liver is about 12-15 g daily. This 
compensatory increase in albumin synthesis 
typically maintains normal plasma albumin 
concentrations during PD and explains why 
peritoneal albumin losses into dialysate are not 
predictive of worse outcome (16); this suggests that 
other factors which can control serum albumin 
levels are responsible of the association between 
serum albumin and mortality in PD patients.  
Similar findings are observed in the 
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proteins is associated with increased synthesis 
of albumin and fibrinogen (36). Of note the 
calculated oncotic pressure has been shown to 
be related to the increase in fractional albumin 
synthesis, suggesting that a change in oncotic 
pressure is the drive for the upregulated liver 
protein production and release (36,37).  
Even if several studies suggest that 
caloric and protein intake and the route of 
administration of the nutrients are major 
nutritional factors regulating albumin synthesis 
(38), wasting due to semistarvation (39) or to 
anorexia nervosa (16) does not lead to 
hypoalbuminemia, indicating an extraordinary 
ability of liver to maintain albumin synthesis 
during nutrient deprivation in absence of 
disease. In keeping with these findings, a weak 
correlation has been observed between protein 
intake and albumin levels in PD patients. 
Kaysen (40) observed that although both 
transperitoneal albumin loss and inflammation 
are strongly associated with serum albumin, the 
two variables are statistically independent. 
Furthermore, he observed no relationship 
between serum levels of C-Reactive Protein 
and transperitoneal albumin losses to account 
for the lower serum albumin levels in patients 
with high loss rates. These findings suggest that 
the increase in albumin synthesis in response to 
transperitoneal albumin loss is blunted by 
inflammation.  
Low oncotic pressure may adversely 
affect water shift between the intravascular and 
interstitial space. Hypoalbuminemia may per se 
be an important determinant of tissue 
overhydration in PD patients because of the 
reduced plasma filling as a result of reduced 
oncotic pressure. Recently John et al. (41), in a 
cross-sectional study, observed that 
overhydration was not associated with an 
increased plasma volume and that the only 
independent predictor of whole body 
overhydration was reduced plasma albumin, 
 
 
which potentially favours extra-vascular, extra-
cellular water accumulation.  
Albumin also has important roles as a 
scavenger of free radicals, it is a binding agent 
for toxic compounds and a carrier for a wide 
variety of drugs and hormones (42). Reduced 
albumin binding of drugs and endogenous 
ligands is a feature of uremia (43). In PD 
patients a state of inflammation directly 
suppresses hepatic albumin synthesis 
preventing compensatory increases in albumin 
production (44).  
Taken together, available data indicate that the 
development of hypoalbuminemia in most PD 
patients appears to be a marker of comorbidity 
and illness rather than a marker of malnutrition 
and is characterized by a combination of the 
acute-phase response, with a reduction in 
serum albumin, combined with a true increase 
in albumin synthesis to compensate for protein 
losses into the peritoneal effluent. 
 
Effects of residual renal function on 
nutrition 
 
The preservation of residual kidney 
function is likely to play an important role in 
the prevention of wasting in PD patients. 
Higher subjective global assessment (SGA) 
scores, dietary protein intake, and dietary 
caloric intake have been observed in patients 
with preserved residual renal function as 
compared to anuric patients 
undergoing PD (45). 
Although underlying mechanisms are 
not known, it is worth to consider that the 
human kidney has a major role on extracellular 
fluid volume overload (which may be 
associated with PEW) (46). In addition the 
human kidney plays a major role on the 
removal of middle molecules and potentially 
toxic low molecular weight proteins (47-49).  
Finally, recent studies show that the 
human kidney plays an important role in the 
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transamination of leucine and essential amino 
acids (50), giving support to the hypothesis that 
defective kidney metabolic activity blunts 
amino acids metabolism. 
 
Effects of peritoneal dialysis “per 
se” on protein metabolism 
 
Peritoneal dialysis can provide a further 
catabolic stimulus in uremic patients. Despite 
substantial glucose absorption, loss of lean 
body mass, with increase or no change in fat 
stores have been reported in longitudinal 
studies in PD patients (4, 51,52). PD patients 
present circulating and intracellular levels of 
essential amino acids (mainly leucine and 
valine) which are even lower than those 
observed in HD patients, which suggests a 
response of protein turnover to depletion or 
reduced release from tissue because of 
hyperinsulinemia (53). 
 
Effects of peritoneal dialysis on whole 
body and muscle protein tunover 
 
Early studies have shown that whole 
body protein degradation declines in response 
to glucose administration (54). Castellino et al.  
(55) observed that basal rates of protein 
degradation, leucine oxidation and whole body 
protein synthesis were reduced in PD patients 
as compared to controls. In addition, during 
euglycemic hyperinsulinemic clamp leucine 
flux declined by about 30% and leucine net 
balance became less negative. When insulin 
was infused together with amino acids, protein 
synthesis rose and leucine balance became  
similarly positive in patients and controls. 
Taken together, data from these studies suggest 
that the response of protein turnover to PD is to 
activate mechanisms to minimize protein loss 
from the body.  
The anticatabolic drive of persisting 
hyperinsulinemia could contribute to the 
 
 
preservation of muscle mass. However, this 
assumption is in contrast with the clinical 
finding of muscle wasting observed in many 
PD patients. In a series of cross-over studies in 
stable, non-malnourished PD patients, we 
evaluated muscle and whole body protein 
dynamics: a) during the systemic, moderate 
hyperinsulinemia associated with the substrate 
removal induced by peritoneal dialysis;  
b) during locally-induced moderate 
hyperinsulinemia, without systemic effects on 
amino acid availability and hormones (56,57). 
During locally-induced moderate hyper-
insulinemia the overall response, which was 
observed both in healthy controls and in CKD 
patients, was a switch from a negative protein 
balance observed in the basal state to a neutral 
one, which was due to an insulin-related 
decrease in protein degradation. These data are 
in accordance with the exquisite sensitivity of 
muscle protein metabolism to insulin. PD with 
dextrose induced a similar increase (by ~2-3 
fold) in insulin levels, and a similar acute 
decrease in muscle protein degradation (56). In 
skeletal muscle, despite the decrease in protein 
degradation, there was not a net anticatabolic 
effect since a concurrent decrease in muscle 
protein synthesis was observed. This decrease 
in muscle protein synthesis correlated with the 
decline in blood of several essential amino 
acids, suggesting that the removal of substrates 
for protein synthesis via peritoneal drainage 
blunts muscle protein turnover. In addition, in 
PD patients, most of the anticatabolic effect of 
insulin was obtained in extra-muscle tissues 
(56,57). Data from these studies indicate that 
PD acutely induces a new state in muscle 
protein dynamics which is characterized by 
decreased turnover rates and a reduced 
efficiency of protein turnover. Accordingly, the 
major effect of PD is to restrain muscle protein 
turnover. On one hand, a reduced rate of 
overall body protein synthesis and breakdown 
might be considered unfavourable, since they  
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would decrease the individual ability to 
whithstand successfully a major stressful 
stimulus. On the other hand, the benefits of a 
high rate of endogenous protein turnover can 
be inferred if one considers that the stimulation 
of growth is accompanied by a high protein 
turnover (58). Because low rates of protein 
turnover may result in a limited potential for 
protein accretion, one could speculate that 
suppression of protein turnover may result in a 
limited potential for net skeletal muscle protein 
anabolism. Taken together, these data suggest 
that glucose-based PD predisposes the body to 
reduced anabolism, a condition which may be 
harmful when nutrient intake is diminished or 
during superimposed catabolic illnesses. 
 
Effects of icodextrin on muscle protein 
metabolism 
 
Icodextrin is a glucose polymer which 
acts as an alternative osmotic agent with an 
osmolarity almost similar to that of plasma. 
Since the absorption of icodextrin by the 
peritoneum is very restricted, icodextrin-based 
solutions cause ultrafiltration (UF) in PD 
patients using colloid osmosis. On nutritional 
ground, the insulin response to icodextrin is 
minimal or absent, but there is a significant 
increase in essential amino acids (EAA) and 
non essential amino acids (NEAA) loss without 
change in plasma levels (59) which suggests 
that icodextrin-based PD favours net protein 
degradation.  
In a pilot study, we evaluated acute effects of 
icodextrin dwell on muscle protein turnover in 
5 non diabetic PD patients.  
Every patient was evaluated twice: at basal 
state and during a 10-12 hours dwell with 
icodextrin. After the icodextrin dwell no 
change in muscle protein degradation and in 
protein synthesis were observed. Net protein 
balance was negative both in basal conditions 
and in response to icodextrin dwell.  
 
 
Protein turnover efficiency was unchanged. 
Consistent with these findings, skeletal muscle 
protein metabolism is not affected by 
icodextrin, suggesting that icodextrin has 
neutral metabolic effects on protein turnover. 
 
Effects of intraperitoneal amino acid 
administration 
 
Changes in muscle metabolism of 
specific amino acids induced by uremia could 
impair both muscle regeneration and protein 
turnover. In patients with CKD a reduced 
release of valine and leucine from muscle is 
likely responsible for their reduced levels in 
blood (60,61). It is of note that leucine 
cooperates with IGF-1 in stimulating the 
activation of satellite cells which are 
responsible for muscle regeneration in different 
situations, such as damage-induced muscle 
loss, aging and progressive neuromuscular 
diseases. The leucine-induced activation of 
satellite cells is obtained through the 
mammalian target of rapamycin (mTOR) 
signaling, one of the main pathways 
responsible for protein synthesis and cell 
proliferation. Of note this signaling pathway is 
partly attenuated in skeletal muscle of 
chronically uremic rats (62).  
With this regard, PD acutely decreases 
leucine levels and further worsens the already 
unbalanced plasma amino acids pattern. Amino 
acids, leucine in particular, can act as strong 
insulin secretagogues when administered in 
combination with carbohydrate. Furthermore, 
amino acids, mainly leucine, have been shown 
to stimulate mRNA translation, thereby 
increasing muscle protein synthesis.  
Different studies have shown that in PD 
patients the use of a 1.1% dialysis solution 
containing all nine essential amino acids, six 
nonessential amino acids and 40 mmol/L 
lactate increases protein synthesis, nitrogen 
balance and weight gain (63-65). 
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However these effects are reported to be mixed 
because of the accompanying metabolic 
acidosis. Asola and coworkers (66) found that 
the use of amino acids solutions increased 
skeletal muscle amino acids uptake as 
compared to the use of glucose-based solutions 
only, both in the fasting state and during insulin 
stimulation. PD solutions containing a mixture 
of amino acids and glucose can serve as a 
source of both proteins and calories but are not 
commercially available. However they can be 
used in patients on automated PD (67). 
Supplying amino acids together with calories 
could bring about utilization of amino acids for 
the synthesis of proteins rather than the 
oxidation of amino acids, thereby limiting 
production of acid and urea. Using dialysis 
solutions with a high buffer concentration (40 
mmol/L) can contribute to maintaining acid-
base homeostasis.  
When we evaluated muscle protein 
turnover during PD with dialysates containing 
dextrose plus amino acids, the decline in blood 
amino acids and in muscle protein synthesis 
was prevented and net protein balance across 
muscle was less negative, indicating that 
increased amino acids availability is a crucial 
determinant of muscle protein turnover in PD 
patients (56). Taken together these data support 
the hypothesis that in patients who are treated 
with PD, when fasting or when nutrient intake 
is reduced, muscle mass could be maintained 
better by the combined use of dextrose and 
amino acids. However, clinical trials are still 
required to evaluate the long-term effects of 
this strategy on morbidity and mortality of PD 
patients.  
Amino acids solutions may induce 
anorexia, metabolic acidosis and increased 
serum urea levels. In addition, the optimal 
formula and amount of amino acids 
supplementation need to be explored further.  
It is unknown if the provision of larger 
quantities of amino acids via PD is safe or 
 
 
efficacious. McCormick et al. (65) 
demonstrated that higher than conventional 
doses of amino acids mixed with glucose can 
be tolerated with relatively minor changes in  
acid-base status provided that a 
bicarbonate/lactate-buffered solution is used. 
 
PEW in uremia: interactions with the effects 
of aging and comorbidities 
 
Sarcopenia is often observed in the aged 
population, and it may express in PD patients 
the combined events occurring in aging and 
renal disease. It is interesting that both 
apoptosis and myostatin are upregulated in 
sarcopenia of aging, suggesting that the 
findings observed in CKD patients may 
represent an acceleration of processes 
‘naturally’ leading to sarcopenia in elderly 
subjects. Elderly patients are expected in 
Western countries to soon become the majority 
of those who will need renal replacement 
therapy. In elderly subjects a decreased 
sensitivity of insulin action regarding protein 
metabolism and selected deficits of myosin 
heavy chain and mitochondrial protein have 
been described (68). These aging-related 
alterations in protein metabolism likely 
potentiate those caused by uremia. PEW is also 
often observed in patients with co-morbid 
conditions, such as sepsis or heart failure. PD 
patients with previous circulatory congestion 
have significantly more inflammation, more 
muscle wasting, and higher energy expenditure 
but lower food intakes in keeping with an 
anorexia-cachexia syndrome (69). It is of note 
that some of the alterations observed in uremia 
overlap with those present in cardiac cachexia. 
Endocrine alterations, such as resistance to  
GH/IGF-1, excess glucocorticoid and 
angiotensin II cause net protein degradation 
and are common to uremic and cardiac 
cachexia (70). In addition, the serum 
concentrations of pro-inflammatory cytokines 
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(mainly TNF-α, IL-6, and IL-1) are known to 
be high in patients with cachexia due to chronic 
heart failure (CHF) and CKD and in both 
conditions they are associated with a poor 
prognosis (71). Studies in animals indicate the 
involvement of multiple catabolic signal 
transduction pathways which may promote 
wasting and impair muscle regeneration in 
uremia and CHF. Emerging data have 
uncovered the role of new mediators such as 
myostatin and activin (72). Myostatin binds to 
the type II receptor ActRIIB, leading to 
phosphorylation of SMAD2 and SMAD3, 
which translocate to the nucleus to regulate 
gene expression. Myostatin stimulation also 
leads to inhibition of the protein kinase B/Akt 
and the mammalian target of rapamycin 
(mTOR) (73). In addition Akt inhibition by 
myostatin increases expression of atrogin-1 
which causes proteosomal degradation (73). 
 
Treatment of wasting in PD patients, new 
approaches 
 
During the last years much progress has 
been made in the understanding of mechanisms 
leading to PEW in CKD and dialysis-treated 
patients. However, the results of intervention 
studies are unsatisfactory (4). There are several 
new issues to be addressed on therapy of PEW 
in PD patients, such as the effects of physical 
exercise combined with amino acids/keto acids 
supplementation, vitamin D, myostatin 
antagonism and ghrelin agonism. Amino acids 
either given via intraperitoneal route or orally 
may have different effects on protein 
metabolism. Substituting a single exchange 
with intraperitoneal amino acids in a patient 
undergoing PD is a potential therapeutic option 
for PEW. This approach may be more 
appropriate for patients with malnutrition 
secondary to reduced protein intake, rather than 
as a result of inflammation in which the extra 
amino acids may not undergo metabolism. 
 
 
Vitamin D is involved in energy 
metabolism and adipocyte biology in vivo in 
part through regulation of β-oxidation and 
uncoupling protein (UCP) expression (74). 
Vitamin D deficiency is highly prevalent in 
patients with CKD and is associated with 
various adverse health outcomes (75). In cross-
sectional studies higher 25(OH) vitamin D 
levels are associated with significantly 
improved survival. Of note, in cohort studies 
vitamin D supplementation improves muscle 
strength, functional ability and balance in both 
CKD and dialysis patients (76). Inadequate 
levels of vitamin D are associated with 
inflammatory factors such as high-sensitivity 
C-reactive protein and neutrophil-lymphocyte 
ratio in a study of a total of 176 hemodialysis 
patients and 32 peritoneal dialysis patients (77). 
However, a metanalysis of interventional 
studies of vitamin D supplementation in CKD 
patients (78) failed to show a clinically evident 
benefit of vitamin D supplementation, besides 
the improvement of biochemical endpoints. 
Specifically, there were insufficient data as for 
cardiovascular and skeletal effects. In addition, 
six months of therapy with calcitriol or 
cholecalciferol did not improve vascular 
endothelial function and did not improve 
inflammation in patients with CKD, in a recent 
study (79). Therefore, whether vitamin D 
supplementation translates into clinically 
significant outcomes is yet to be determined. 
 
Another potential initiator of muscle 
wasting is myostatin which is upregulated in 
muscle of animal models of uremia, in patients 
with CKD and cardiac cachexia. Recently, 
pharmacologic suppression of myostatin was 
found to counteract inflammation and impaired 
insulin/IGF-1 signaling and most importantly, 
it prevented muscle wasting in rodent models 
of cancer and kidney failure (80). These lines 
of evidence highlight the therapeutic potential 
of myostatin antagonism for treating sarcopenia
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by inhibiting protein degradation and/or 
apoptosis. In fact a recent experimental study 
demonstrated that vitamin D receptor agonists 
(VDRAs) stimulates myogenic differentiation 
by inhibiting cell proliferation, by increasing 
the expression of pro-myogenic factors and by 
depressing the expression of myostatin mRNA 
(81). 
 
A clinical study showed that vitamin D 
supplementation increases skeletal muscle mass 
in CKD patients (82).  
A more recent experimental study showed that 
ablation of vitamin D receptor or vitamin D 
deficiency increased myostatin expression and 
decreased skeletal muscle mass in mice (83). 
 
Recently, a small randomized trial 
demonstrated that oral supplement with ONCE 
(Otsuka Nutrition Pharmaceutical) dialyze 
formula (ODF) ameliorates low dietary energy 
and nutrient intake as well as improves serum 
prealbumin and body weight in patients with 
long-term CAPD (84). 
 
Furthermore, improving fluid status is 
associated with better nutritional status and 
worse fluid status results in malnutrition. In 
peritoneal dialysis patients, volume overload 
causes low intake of calories and of dietary 
proteins (85). Fluid overload may be associated 
with higher serum endotoxin and inflammatory 
cytokines levels in PD patients (86). Elevated 
levels of proinflammatory cytokines suppress 
appetite and induce anorexia by inhibiting the 
adaptive feeding response to energy deficits 
(86-88). Inflammation results in loss of muscle 
mass by activating the ubiquitin-proteasome 
proteolytic pathway (89,90). Controlling fluid 
overload can improve systemic endotoxin level, 
inflammation and then malnutrition (85, 91). 
 
Taken together, these evidences suggest 
that substituting one glucose peritoneal dialysis  
exchange with icodextrin improves 
 
 
malnutrition and reduces systemic 
inflammation. Icodextrin dialysis remarkably 
reduces high sensitive C reactive protein 
(hsCRP) levels and other inflammatory 
markers, likely because of a better fluid balance 
(92). Other mechanisms, other than fluid 
balance, are implicated with beneficial effects 
with icodextrin use. Dialysis using icodextrin 
excange decreases leptinoemia (93), a hormone  
that suppresses appetite. Furthermore 
substitution of glucose for icodextrin, 
decreasing glucose exposition, reduces insulin 
resistance, both in diabetic and in non-diabetic 
patients (94). Insulin is an anabolic that exerts 
anticatabolic effects on skeletal muscle. Insulin 
resistance might dampen the anabolic effect of 
insulin on skeletal muscle and might cause loss 
of muscle mass. Indeed, insulin resistance 
correlated with muscle wasting in 21 patients 
on peritoneal dialysis, which suggests that 
insulin resistance is closely linked to PEW 
(95). 
 
A high prevalence of low-performance 
capacity and sedentarism has been found 
among elderly patients on PD or with CKD 
stage 3-4. Apart from age, a condition of 
malnutrition-inflammation was the major 
determinant of poor physical activity and 
capacity in PD patients. Better body 
composition seems to be positively associated 
with physical activity in PD. Routine clinical 
management should include a close evaluation 
of nutritional status and of physical activity and 
capacity (96). Cobo et al. reported a high 
prevalence of sedentarism (63%) in a cohort of 
64 PD patients as assessed by pedometers. 
They detected that better physical activity was 
associated with lower comorbidity and better 
nutritional status (depicted by albumin and 
subjective global assessment), higher lean body 
mass and lower fat body mass. Higher levels of 
physical activity were accompanied by lower 
levels of C-reactive protein in PD (97).The 
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relationship between nutritional status and 
physical activity is of special value in PD 
patients, who are both at high risk of protein 
depletion and at risk of obesity (98). Recently,  
a 6-month multicenter, randomized clinical trial 
demonstrated the utility of a simple, 
personalized walking exercise program at 
home, managed by dialysis staff, in improving 
functional status in adult patients on dialysis. 
The main study outcomes included change in 
physical performance at 6 months assessed by 
the 6-minute walking test and the five times-
sit-to-stand test and in quality of life (99). 
 
In this setting, implementation of a regular 
physical activity could contribute to maintain 
muscle mass/strenght/functionality and to 
increase energy expenditure. Achieving better 
 
 
muscle functionality may in fact be a step 
toward improved physical functioning and 
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